title: Catatonia in Neurologic and Psychiatric Patients at a Tertiary Neurological Center.
abstract: This study describes the prevalence, phenomenology, treatment, and outcome of neurological patients and psychiatric patients with catatonia at a tertiary neurological center. Clinical variables included nosological diagnoses and complications. Admission length and days with catatonia were used as outcome measures. Of 2,044 patients who were evaluated prospectively, 68 (3.32%) had catatonia, 42 (61.7%) were neurological patients, 19 (27.9%) were psychiatric patients, and 7 (10.2%) had drug-related diagnoses. Of all patients, the ratio of neurological to psychiatric patients was 3:1. Encephalitis was the most common diagnosis (N=26 [38.2%]), followed by schizophrenia (N=12 [17.6%]). Psychiatric patients exhibited a stuporous type of catatonia (15 [83.3%] versus 14 [33.3%], p>0.001), whereas neurological patients exhibited a mixed form of catatonia (25 [59.5%] versus 1 [5.6], p<0.001). Neurological patients had more complications, longer hospitalizations, and more days with catatonia. A total of 56 patients (82.3%) received lorazepam, and 14 patients (20.5%) underwent ECT. Second- and third-line treatments included amantadine, bromocriptine, and levodopa. Catatonia is a prevalent syndrome that can remit with proper and opportune treatment.
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: Mariana
authors.initials: M
authors.lastname: Espinola-Nadurille
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: Jesus
authors.initials: J
authors.lastname: Ramirez-Bermudez
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Fricchione
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Ojeda-Lopez
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: Andres F
authors.initials: AF
authors.lastname: Perez-González
authors.affiliation: From the Neuropsychiatric Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico (ME-N, JR-B, MCO-L, LCA-V); the Division of Postgraduate Studies, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico (ME-N, JR-B); the Division of Psychiatry and Medicine, Dept. of Psychiatry, Massachusetts General Hospital, Boston (GLF); and the Dept. of Psychiatry, Antioquia University, Colombia, South America (AFP-G).
authors.forename: Luis C
authors.initials: LC
authors.lastname: Aguilar-Venegas
mesh_terms: D000293:Adolescent; D000328:Adult; D002389:Catatonia / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D015897:Comorbidity; D004660:Encephalitis / Q000453:epidemiology* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012559:Schizophrenia / Q000453:epidemiology* / Q000628:therapy; D055815:Young Adult